M
Marker Therapeutics D
D
MRKR
1.41000
USD
-0.03
(-2.08%)
مغلق
حجم التداول
330
الربح لكل سهم
-1
العائد الربحي
-
P/E
-3
حجم السوق
23,509,109
المقالات
العنوان: Marker Therapeutics
القطاع: Healthcare
الصناعة: Biotechnology
Marker Therapeutics Inc is a clinical-stage immuno-oncology company specializing in the development and commercialization of novel T cell-based immunotherapies and peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. The company develops product candidates from MAR-T cell technology, which is based on the selective expansion of non-engineered, tumor-specific T cells that recognize tumor-associated antigens, or TAAs, which are tumor targets, and then kill tumor cells. These T cells are designed to recognize multiple tumor targets to produce broad spectrum anti-tumor activity. Its pipeline products include: Autologous MAR-T cell product for the treatment of lymphomaand pancreatic cancer (MT-601), and Off-the-Shelf (OTS) products (MT-401-OTS).
